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Abstract
Background:  The discovery of a "serrated neoplasia pathway" has highlighted the role of
hyperplastic lesions of the colon as the significant precursor of colorectal adenocarcinoma. In mice,
hyperplasia of the colonic mucosa is a regular phenomenon after a challenge with colonic
carcinogens indicating that mucosal hyperproliferation and thickening, even without cytological
dysplasia, represents an early pre-malignant change. Cyclophilin C-associated protein (CyCAP) has
been described to down-modulate endotoxin signaling in colorectal murine mucosa and is a murine
orthologue of the tumor-associated antigen 90 K (TAA90K)/mac-2-binding protein.
Methods: Female Balb/c wild-type (WT) and CyCAP knock-out (KO) mice (6–8 weeks old) were
administered 2 or 6 weekly subcutaneous injections of azoxymethane. The animals were evaluated
post-injection at six weeks for aberrant crypt foci (ACF) study and at five months for colon tumor
measurement. The thickness of the colon crypts was measured in microns and the number of
colonocytes per crypt was also determined in well-oriented crypts. Morphometric analyses of the
colon mucosa were also performed in untreated 6–8 weeks old KO and WT animals. Formalin-
fixed/paraffin-embedded colon sections were also studied by immunohistochemistry to determine
the Ki-67 proliferation fraction of the colon mucosa, β-catenin cellular localization, cyclin D1, c-
myc, and lysozyme in Paneth cells.
Results:  Cyclophilin C-associated protein (CyCAP)-/- mice, spontaneously developed colonic
mucosal hyperplasia early in life compared to wild-type mice (WT) (p < 0.0001, T-test) and crypts
of colonic mucosa of the (CyCAP)-/- mice show higher proliferation rate (p = 0.039, Mann-Whitney
Test) and larger number of cyclin D1-positive cells (p < 0.0001, Mann-Whitney Test). Proliferation
fraction and cyclin D1 expression showed positive linear association (p = 0.019, Linear-by-Linear
Association). The hyperplasia was even more pronounced in CyCAP-/- mice than in WT after
challenge with azoxymethane (p = 0.005, T-test). The length of the crypts (r = 0.723, p = 0.018,
Spearman Correlation) and the number of colonocytes per crypt (r = 0.863, p = 0.001, Spearman
Correlation) in non-tumorous areas were positively associated with azoxymethane-induced
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number of tumors. CyCAP-/- developed larger numbers of tumors than WT animals (p = 0.003, T-
Test) as well as overall larger tumor mass (p = 0.016, T-Test). Membranous β-catenin was focally
overexpressed in KO mice including proliferative zone of the crypts.
Conclusion:  CyCAP-/- represent the first described model of spontaneous colonic mucosal
hyperplasia. We conclude that CyCAP-deficient mice spontaneously and after challenge with
carcinogen develop significantly more colorectal mucosal hyperplasia, an early stage in murine
colonic carcinogenesis.
Background
Colorectal cancer remains a significant cause of morbidity
in Western countries [1]. Colorectal carcinoma evolves
through multiple pathways (recently reviewed by Jass J.
R.)[2]. For many years clinical practice has been focused
on early detection and removal of adenomatous polyps by
screening colonoscopy is an important strategy for reduc-
ing the risk of developing colon cancer [3]. Colorectal ade-
noma is considered to be a precursor of about 70%
colorectal carcinomas, those that are characterized by
chromosomal instability and are microsatellite stable. It
appears that as many as 20% of colorectal carcinomas
may originate by serrated neoplasia pathway [2]. It has
become apparent that clinical management of lesions tra-
ditionally diagnosed as "hyperplastic polyps" and gener-
ally considered as benign lesions with no malignant
potential, may need to change because of the malignant
potential associated with some types of serrated polyps
including so-called "traditional serrated adenoma" and
"sessile serrated adenoma" [1,4-6].
Hyperplasia of the human colon is found in several forms
including focal mucosal hyperplasia in hyperplastic
polyp, the thickening of the mucosa surrounding colon
carcinoma or adenoma, which is termed "transitional
mucosa", and regenerative hyperplasia, which may occur
in a variety of inflammatory conditions. All of these
lesions are considered to be benign, harmless lesions,
with no proven premalignant potential [7-9]. Sessile ser-
rated polyp is a newly described type of serrated polyp,
now recognized as a main actor in a so-called "serrated
pathway" of colon carcinogenesis and it shares many fea-
tures with the common hyperplastic polyp [5,10,11].
Therefore in humans, two types of colonic serrated
mucosal hyperplasia can be distinguished; non-preneo-
plastic and preneoplastic. Most forms of mucosal thicken-
ing of the colon are due to reactive epithelial hyperplasia
and do not lead to malignancy, which is in contrast to
mice in which mucosal hyperplasia develops as the first
change and also in parallel with colonic epithelial tumors
after the treatment with carcinogens [12].
The above observations in humans are in agreement with
the notion that not all hyperplastic agents have tumor-
promoting activity [13]. For instance, TGF- alpha is a
potent  in vivo epithelial mitogen which promotes dra-
matic hyperplasia in the colon, but does not lead to any
alteration in colonic tissue architecture or colonic tumors
[14]. TGF- alpha was also found to be absent in ACF in
rats and there was reduced amounts of TGF- alpha expres-
sion in the upper part of the aberrant crypts compared
with the surrounding normal crypts [15]. Although the
absence of TGF-alpha was unexpected, it was in accord-
ance with observations from recent in vitro studies which
demonstrated that the presence of TGF-alpha in the top of
the colonic crypt serves to inhibit growth of differentiated
colonic epithelial cells [16,17]. In humans, lower levels of
TGF-alpha are present in the distal part of the colon,
which is the most common site of tumor formation [18].
Additionally, non-preneoplastic secondary mucosal
hyperplasia as a reaction to a colonic tumor, so-called
"transitional mucosa", possibly develops due to tumoral
secretion of IL-15 [19].
Despite these findings, it has been established that thick-
ened and serrated colonic mucosa at least in the form of
sessile serrated adenoma (synonymously referred to as
"atypical hyperplasia"), represents a morphologic entity
of the serrated neoplasia pathway [2,20]. The discovery of
different subtypes of serrated polyps enabled morpho-
logic separation of the harmless hyperplastic lesions from
those that are likely to be precancerous [4,6]. It is possible
that precancerous serrated polyps of the colon represent a
human homologue of the murine pre-neoplastic hyper-
plasia induced by carcinogens since these represent the
only form of "hyperplasia" of human colonic mucosa that
has been biologically linked to colorectal carcinoma [2].
The tumor-associated antigen 90 K (TAA90K) [21,22],
also known as Mac-2-binding protein or 90 K, is a secreted
90–100 kDa glycoprotein widely expressed in human flu-
ids [23], tumor derived cell lines including those with epi-
thelial differentiation [24-28] and elevated in the serum
of cancer patients [Iacobelli et al., 1993; Natoli et al., 1993;
Iacobelli et al., 1994; Greco et al., 2004] as well as sufferers
from other nonmalignant diseases such as AIDS [29,30].
It is a member of the scavenger-receptor cysteine-rich
domain superfamily implicated in development and reg-
ulation of the immune system [31]. On the other hand, its
aberrant expression by epithelial neoplastic cells has alsoBMC Cancer 2009, 9:251 http://www.biomedcentral.com/1471-2407/9/251
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been described. Elevated expression of TAA90K has been
detected in breast, gastric, lung and pancreatic cancers
[32-35] and, in the cases of lung cancer and malignant
mesothelioma [33,34], protein levels correlated with
metastasis and predicted survival or disease manifesta-
tion. In a recent study [36], we have also detected elevated
TAA90K expression in colorectal adenocarcinoma.
Although the function of aberrantly expressed TAA90K in
cancer is unclear, it has been shown to mediate β1-
integrin-dependent cell adhesion [37], interact with vari-
ous extracellular proteins including extracellular matrix
proteins and galectins [36-38], and stimulate expression
of promatrilysin [39], previously implicated in colon can-
cer progression [40].
However, the primary and physiological role of TAA90K
appears to be, according to the current knowledge, in
immune regulation. This glycoprotein has been shown to
be a potent immune stimulator with positive effects on
the generation of cytotoxic effector cells (NK/LAK) from
human peripheral blood mononuclear cells (PBMC)
[41,42]. In fact, 90 K in human milk may be protective
against acute respiratory infections [43]. The protective
effect seems to be related to the amount of 90 K ingested
during the first few days, as milk 90 K concentrations sub-
sequently decline rapidly in all mothers [44]. These find-
ings suggested that 90 K initiates a defense mechanism in
the infant early in life.
In recent years, cyclophilin C-associated protein (CyCAP)
has been identified as the murine orthologue of TAA90K
with up to 80% homology in their amino acid sequence
[45,46]. CyCAP is a widely expressed secreted glycopro-
tein that modulates the host response to bacterial endo-
toxin [47]. In response to endotoxin, CyCAP-deficient
mice overproduced interleukin 12 and interferon-γ sys-
temically and tumor necrosis factor α locally, proinflam-
matory molecules that also promote T helper 1 responses.
Furthermore, macrophages stimulated in vitro with endo-
toxin in serum deficient CyCAP-null cells secreted more
TNF-α, supporting the proposal that CyCAP specifically
down-modulates endotoxin signaling [47].
In this report, we have examined the contribution of
CyCAP to colon hyperplasia and tumorigenesis in vivo
before and after injection of the colon carcinogen
azoxymethane as a possible animal model suitable for
elucidating the role of TAA90K in colon tumorigenesis
and progression, thereby providing a level of biological
understanding not readily available in clinical disease.
Methods
Animals and azoxymethane treatment
Female Balb/C mice (6–8 weeks) were obtained from the
Animal Resources Center (University of Saskatchewan,
Saskatoon, SK). Breeding pairs of Balb/C CyCAP knock-
out mice were obtained from Dr. I. Weissman (Stanford
University, San Francisco, CA) and used to set up an in-
house breeding colony. Forty seven animals were tested
routinely for the presence of pathogens. In particular,
mice were free of Citrobacter freundii, a bacterium associ-
ated with transmissible intestinal hyperplasia [48]. All
experimental procedures were carried in accordance with
guidelines from the Canadian Council on Animal Care.
Forty seven female Balb/c wild-type and CyCAP knock-
out mice (6–8 weeks old) were administered 6 weekly
subcutaneous injections of azoxymethane (10 mg/kg)
(Midwest Research Institute, MO) [49] for measurements
of ACF or colon tumor incidence, respectively, using pro-
cedures described previously [50]. Six weeks (ACF meas-
urement) or five months (colon tumor measurement)
post-injection, animals were sacrificed, the intestine
removed and washed in ice-cold PBS. Colons were cut
longitudinally, laid flat between two pieces of 3 mm filter
paper and fixed for at least two hours in formalin (10%
formaldehyde in phosphate buffered saline pH 7.0). For
ACF and tumor measurements, colons were stained for 5
min in a solution of 1% methylene blue in PBS and
destained for 5 min in PBS. Stained colons were examined
microscopically for the presence of ACF, as described by
Bird et al. [51] and also for the presence of tumors. The
size of tumors (length in mm × width in mm) was meas-
ured at a magnification of 40× using a gradicule (Precision
Instruments, Vancouver, BC) calibrated with a slide
micrometer. After the data were collected, the fixed colons
of 5 untreated and 5 azoxymethane-treated wild-type and
CyCAP knock-out animals were embedded in paraffin.
Hematoxylin and eosin-stained five micron-thick serial
sections were examined histologically.
Measurements and cell counts
All measurements and cell counts were performed on his-
tologically non-tumorous mucosa, with no definite path-
ological findings. The exact absolute length of each
colonic crypt was measured in μm and the exact absolute
number of cells per each crypt was recorded. In addition,
only areas away from the tumors and lymphoid aggre-
gates were measured to avoid so-called traditional mucosa
or reactive changes. The thickness of the crypts was meas-
ured in microns in 60 to 246 well-oriented crypts (all
available well-oriented crypts were measured) using a cal-
ibrated camera (Nikon Digital Sight DS-SM, Japan)
mounted on the microscope (Nikon Eclipse 80i, Japan).
The presence of the full thickness of the crypt with open
lumen, to avoid tangentionally-sectioned crypts, was the
only positive selection criterion. The same method was
used for establishing the crypt proliferation fraction as
measured by the number of Ki-67+ cells divided by the
total number of cells per crypt. Immunohistochemical
tests for Ki-67, cyclin D1, c-myc, lysozyme, and β-catenin
were done as previously described [52,53]. In the majorityBMC Cancer 2009, 9:251 http://www.biomedcentral.com/1471-2407/9/251
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of animals, a total of 60 accounted for most of the well-
oriented crypts. The number of colonocytes per crypt was
also determined in at least 60 well-oriented crypts per ani-
mal. B-catenin was evaluated for cellular localization and
its nuclear, cytoplasmic, and membranous was recorded.
The intensity of staining and its distribution was recorded
in 60 well-oriented crypts using semiquantitative scale (0-
negative, 1-weak membranous staining, and 2-strong
membranous staining), as well as the anatomical location
of the positive cells in the mucosa (crypt base, crypt body,
and colonic plate).
Statistical analysis
Descriptive statistics were used to summarize data. Initial
descriptive analyses were done to determine whether to
use parametric t-test or non-parametric Mann-Whitney
test for mean comparisons and whether to assume equal
variance or unequal variance. A Student's t-test was used
to examine the differences for continuous variable under
assuming either equal or unequal variance. Association
between variables were determined using Spearman corre-
lation coefficient analysis. Linear regression model were
also used after checking assumption of linearity, normal-
ity and constant variance of independent error. A p-value
of less than 0.05 was considered statistically significant.
The analysis was performed using the SPSS – 15 software.
Results
Correlation between the number of cells per crypt and the
length of the crypt was significant (p < 0.0001, Spearman
Correlation). The coefficient of correlation was 0.86. This
result indicated that the increased length of the crypts was
due to hyperplasia, rather than hypertrophy or other phe-
nomena like edema or various artifacts.
All available well-oriented crypts were evaluated for the
number of cells per crypt as well as for the absolute length
of the crypt. The number of observations (N) per animal
varied from 60 to 246 per animal depending on the
number of available well-oriented crypts. The results are
summarized in Tables 1 and 2 and Figure 1, 2, 3, 4, 5, 6,
and 7. The length of the crypts in CyCAP null mice and
WT mice (r = 0.723, p = 0.018, Spearman Correlation) as
well as the number of colonocytes per crypt (r = 0.863, p
= 0.001, Spearman Correlation) in non-tumorous areas of
the colon were positively associated with total number of
tumors induced by azoxymethane (Figure 1 and 2). Also,
the length of the crypts (r = 0.782, p = 0.008, Spearman
Correlation) and the number of colonocytes per crypt (r =
0.927, p < 0.0001, Spearman Correlation) in non-tumor-
ous areas of the colon of CyCAP null mice and WT mice
correlated with the total size of the tumors. In addition,
untreated 8-week old CyCAP null mice had significantly
thicker mucosa and significantly larger numbers of
colonocytes per crypt (hyperplasia) (p < 0.0001, T-test), as
well as higher proliferation fraction as measured by Ki-67
immunohistochemical test (p = 0.032, Mann-Whitney
Test) even before azoxymethane treatment was initiated
(Figure 1, 2A, and 3) indicating spontaneous develop-
ment of mucosal hyperplasia. The difference in diffuse
mucosal thickness was even more pronounced after the
treatment with carcinogen (p < 0.0001, T-test, Figure 2A,
3, 4, and 5). Similarly, the null mice had larger numbers
of cells per crypt both before (p = 0.032, Linear Regres-
sion; plots not shown) and after treatment with carcino-
gen (p = 0.012, Linear Regression; plots not shown)
compared with WT animals.
CyCAP null mice had significantly larger numbers of ACF
and tumors per animal than control WT animals (p =
0.016, T-Test, Figure 2B). The mean tumor size was larger
in CyCAP null mice (p = 0.031, T-Test) as well as cumula-
tive tumor size per animal (p = 0.003, T-Test, Figure 2C).
Spectrum of histologic changes is shown in Figure 6.
Beta-catenin was not detected in the nuclei of the colono-
cytes either in WT or KO mice. Membranous β-catenin
was overall less expressed in WT mice than in KO mice (p
< 0.0001, Mann-Whitney Test). In WT mice, β-catenin was
very weakly expressed in the colonic crypts with more
notable expression in the colonic plate/luminal surface of
the mucosa (Figure 7A). Membranous β-catenin in CyCAP
KO mice is not only overall stronger, but also there is
strong expression not only in the colonic plate, but focally
also in an irregular fashion including the base of the crypts
(Figure 7B). The difference between WT and KO mice in
the distribution of β-catenin expression was also highly
significant (p < 0.0001, Mann-Whitney Test). This overex-
pression of the membranous β-catenin is highly variable
from one crypt to another. No definite difference in c-myc
expression between WT and KO mice was noted. Cyclin
D1 expression was significantly higher in KO mice (p <
0.0001, Mann-Whitney Test) and also positively corre-
lated with Ki-67 expression (p = 0.019, Linear-by-Linear
Association).
Discussion
Historically, it has been claimed that the transition from
hyperplasia to neoplasia is frequent [54,55]. Human stud-
ies and experimental data from animals suggest that high
rates of colonic epithelial cell replication enhance the
development of colon cancer [56-58]. Exaggerated
mucosal proliferative activity is in some way associated
with the development of large-bowel neoplasia. Individu-
als with inflammatory and proliferative diseases of the
bowel such as Crohn's disease, ulcerative colitis, and
familial polyposis suffer an unusually high risk and early
onset of colorectal cancer. However, as mentioned above,
this has never been shown in a very common form of
colonic mucosal hyperplasia, i.e. hyperplastic polyps [59]BMC Cancer 2009, 9:251 http://www.biomedcentral.com/1471-2407/9/251
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and no evidence of diffuse hyperplasia was ever detected
in patients with colorectal carcinoma despite demonstra-
ble abnormalities in cell kinetics in histologically normal
mucosa in some patients with adenocarcinoma [60] ade-
nomatous polyps [61], familial polyposis [62], and ulcer-
ative colitis [63].
The hyperplasia-neoplasia model has also been chal-
lenged at least by one experiment in rodents [64] in which
experimentally produced megacolon was associated with
reactive mucosal hyperplasia, but showed less malignant
tumors than rats without megacolon, both treated by
dimethylhydrazine for 20 weeks. One possible interpreta-
tion of these results would suggest that experimentally
induced reactive hyperplasia is not a premalignant condi-
tion and may even be protective of neoplastic transforma-
tion. This is in contrast with our findings of increased
number of tumors developing in animals with more pro-
Distribution of colonic mucosal measurements in WT and KO mice Figure 1
Distribution of colonic mucosal measurements in WT and KO mice. Histograms of measurements illustrate distribu-
tion of crypt length in wild type and CyCAP-/- animals.BMC Cancer 2009, 9:251 http://www.biomedcentral.com/1471-2407/9/251
Page 6 of 11
(page number not for citation purposes)
nounced mucosal hyperplasia suggesting that colorectal
hyperplasia in our model is a preneoplastic change.
In mice, colonic mucosal hyperplasia can be caused by
infection. Transmissible murine colonic hyperplasia is the
only naturally occurring hyperplastic disease of the colon
in mice [65]. This severe but transient mucosal hyperpla-
sia of the distal colon is caused by Citrobacter freundii [48]
and was shown to have an expansion of the proliferative
zone, an increased labeling index, a prolongation of the
cell cycle time, an increase in variation of DNA synthesis
times resulting in prolongation of the S phase, and an
accelerated migration rate [66]. Interestingly, these find-
ings parallel the "atypical" kinetics found in human and
murine preneoplastic and neoplastic disorders of the
colon, and also abnormal proliferative kinetics which
occur in the flat mucosa of humans between existing
tumors or polyps and in the preneoplastic mucosa of
rodents treated with carcinogens [60,62]. Hyperplasia,
analogous to tumor promoters which induce proliferation
The differences in the measured crypt length were significant before and after treatment by azoxymethane Figure 2
The differences in the measured crypt length were significant before and after treatment by azoxymethane. 
CyCAP-/- animals spontaneously developed increased crypt length and also developed much more exuberant response to 
azoxymethane treatment (A), which resulted in more hyperplasia (A) larger number of adenomas (p = 0.003, Linear Regres-
sion) (B) and increased cumulative size of adenomas (p = 0.016, Linear Regression) (C). The CyCAP-/- untreated animals also 
spontaneously developed higher crypt proliferation ratio (p = 0.039, Mann-Whitney Test) (D).BMC Cancer 2009, 9:251 http://www.biomedcentral.com/1471-2407/9/251
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[12], has been shown to reduce the lag period for the
appearance of carcinogen-induced neoplastic lesions and
to allow their induction with single, subthreshold doses
of carcinogen. Our data indicate that the CyCAP null mice
spontaneously develop thicker and more proliferative
mucosa of the colon, which allowed for marked induction
of both additional mucosal hyperplasia and mucosal
tumors after the treatment with carcinogen and is in agree-
ment with previous studies, which have indicated that
mucosal hyperplasia has a profound effect upon early car-
cinogenesis [67,68].
Intraluminal factors including western-style diet/food
were found to produce colonic mucosal hyperplasia in
experimental animals [69,70]. However, Delvaux et al.
[71] detected an increase in colonic cell proliferation
within an excluded colostomy segment. It was also
recently demonstrated that serum insulin levels directly
correlate with the presence of adenoma and hyperplastic
polyps in the proximal colon of humans [72]. The history
of tobacco smoking was also associated with higher inci-
dence of hyperplastic polyps [59]. The latter studies sug-
gested that extraluminal factors may also play an
important role in the regulation of colonic mucosal
growth. Immune regulation and host defense may repre-
sent one additional extraluminal factor in regulation of
The CyCAP-/- mice spontaneously develop colonic mucosal  hyperplasia early in life at 6–8 wk Figure 3
The CyCAP-/- mice spontaneously develop colonic 
mucosal hyperplasia early in life at 6–8 wk. The differ-
ence between this hyperplastic mucosa and normal mucosa 
of the WT mice is inconspicuous by superficial observation, 
but statistically, the difference is significant (p < 0.0001, T-
test) (20 × magnification, H&E).
The differences in the crypt length and crypt cell content are  more obvious between WT and KO animals after the treat- ment by azoxymethane Figure 4
The differences in the crypt length and crypt cell con-
tent are more obvious between WT and KO animals 
after the treatment by azoxymethane. After the treat-
ment by azoxymethane, the CyCAP-/- mice develop more 
extensive mucosal hyperplasia of the colon than WT animals 
(p < 0.0001, T-test). The mononuclear inflammatory content 
in the lamina propria is not increased compared to WT ani-
mals (20 × magnification, H&E).
In many early adenomas after azoxymethane treatment,  hyperplastic-like changes were also present Figure 5
In many early adenomas after azoxymethane treat-
ment, hyperplastic-like changes were also present. 
Adenomatous changes without (A) and with (B) evidence of 
cytologic dysplasia and cystically dilated crypts and hyperplas-
tic changes in close proximity to muscularis mucosae were 
found in tumors after azoxymethane treatment (20 × magni-
fication, H&E).
Spectrum of histologic changes in KO mice treated by  azoxymethane Figure 6
Spectrum of histologic changes in KO mice treated 
by azoxymethane. Early dysplastic changes were noted in 
many areas, some of which corresponded to ACF (A). More 
extensive moderate dysplasia was noted in areas of thickened 
mucosa (B) and in tumors/adenomas (C). Focal severe dys-
plasia/carcinoma in situ changes were also note (D).BMC Cancer 2009, 9:251 http://www.biomedcentral.com/1471-2407/9/251
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colonic mucosal growth. Suzuki et al. [73] developed an
experimental hyperplasia in nu/nu mice by transfer of
lymphocytes from the C57BL/6 mice infected by murine
leukemia virus (LP-BM5). Lymphocyte transfer to nu/nu
mice induced colitis and hyperplasia of intestinal epithe-
lial cells. In contrast to CyCAP null mice in our study,
which did not show any mucosal inflammation in addi-
tion to the hyperplasia, these mice developed marked
mononuclear infiltrates rich in CD4+/CD45RBlow T-cells.
Suzuki et al. [73] work shows that in such model, hyper-
plasia of the colon may be due to defects in immunoreg-
ulatory mechanisms. TAA90K belongs to an ancient
protein superfamily which is defined by a scavenger recep-
tor cysteine-rich (SRCR) domain [41]. It is particularly
noteworthy that all the previously characterized SRCR
domains occur in proteins involved in or thought to par-
ticipate in critical functions of the cellular host defense
system, and thus they resemble the immunoglobulin
superfamily of the cysteine-containing protein domains
(reviewed in ref. 31). Histochemically, Mac-2 has been
located intracellularly in many members of the macro-
phage lineage, including tissue macrophages, certain den-
dritic cells, alveolar and Kupffer cells [74,75].
Importantly, Jallal et al. [23] showed that engineered
enhancement of 90 K expression results in significant (>
80%) tumor growth inhibition, not by direct action on
the tumor cells, but by stimulation of the residual cell-
mediated immune defense of the nude mouse.
Recently, Rigby at al. [76] showed a role of suppressor of
cytokine signaling-3 (SOCS3) in colonic mucosal epithe-
lial proliferation. Mice with disrupted SOCS3 gene
responded with increased proliferation and increased
crypt depth after acute dextran sodium sulfate(DSS)-
induced mucosal injury or after azoxymethane and
chronic DSS. However, the authors did not report sponta-
neously developing mucosal hyperproliferation and
mucosal hyperplasia as it was the case in CyCAP deficient
mice in our study. Similarly, Jones et al. [77] reported that
conditional deletion of beta-1 integrins in the intestinal
epithelium causes a loss of Hedgehog expression and
intestinal hyperplasia. However, images illustrated in
their publication reveal architectural abnormalities and
cytologic atypia, both of which are indicating develop-
ment of ectopic crypts and adenomas rather than simple
lengthening of the crypts, which would indicate hyperpla-
sia only.
Wnt/β-catenin signalling is critically important for colon
organogenesis and also for colon carcinogenesis. Wnt pro-
tein binding to Frizzled (Fzd) and low-density lipoprotein
receptor-related proteins (LRP) causes inactivation of gly-
cogen synthase kinase (GSK) 3β and Axin, respectively.
The inactivation of these proteins stabilizes β-catenin,
which subsequently accumulates in the cell nucleus and
activates the transduction of target genes that are crucial in
the G1-S-phase transition and therefore, nuclear β-catenin
co-localize with markers of proliferation including c-myc
Table 2: Independent Samples T-Test for Equality of Means
Animal Type* Sig. (2-tailed) Mean Difference Std. Error Difference Lower
95% CI**
Upper
95% CI**
Type 1 vs. 2 < 0.0001 42.83620 4.19191 34.60355 51.06885
Type 3 vs. 4 < 0.0001 15.40680 2.52900 10.43976 20.37384
Type 1 vs. 3 < 0.0001 61.26872 3.36607 54.65772 67.87973
Type 2 vs. 4 < 0.0001 88.69812 3.58972 81.64806 95.74819
* Animal type as per Table 1. ** Confidence Interval of the Difference
B-catenin cellular localization in WT and CyCAP KO mice Figure 7
B-catenin cellular localization in WT and CyCAP KO 
mice. In WT mice, β-catenin expression is higher in the 
colonic plate than in the crypts of the colon mucosa (A). 
However, CyCAP KO mice show overall increased membra-
nous expression of β-catenin with irregular distribution, 
which focally significantly extended into crypts (B). No defi-
nite nuclear localization of β-catenin was detected either in 
WT or KO mice.
Table 1: Distribution of Mean Thickness and SD of Non-Tumoral 
Colonic Mucosa
Animal Type Mean (μm) SD
Type 1: WT + A 182.5761 48.53183
Type 2: KO + A 225.4123 54.00269
Type 3: WT 121.3074 30.88762
Type 4: KO 136.7142 30.33236
SD = Standard Deviation, A = Azoxymethane, WT = Wild Type Mice, 
KO = Knock Out MiceBMC Cancer 2009, 9:251 http://www.biomedcentral.com/1471-2407/9/251
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and cyclin D1, and Ki-67 [78,79]. This pathway also has a
critical role in Paneth cell differentiation [80]. We have
not observed any morphological or immunohistochemi-
cal evidence of increase or aberrant localization of Paneth
cells in the colon specimens of the CyCAP knockout mice.
Also, no abnormalities of Paneth cells were identified in
the small intestine of the CyCAP KO mice. While β-cat-
enin was not detected in the nuclei of the colonocytes in
either WT or KO mice and there were no definite differ-
ence in expression of the c-myc and cyclin D1, KO mice
had increased membranous β-catenin expression com-
pared to their matched WT control and strong expression
of  β-catenin was also detected in all segments of the
colonic crypts including the base indicating that prolifer-
ative zone shows β-catenin phenotype that is seen only on
the colonic plate of normal mice. Since one way by which
cytoplasmic β-catenin is prevented from returning to the
nucleus is by being locked by the emerging E-cadherin
into adherens junctions which link the cell to prolifera-
tively shut-down functioning cells moving up and out of
the crypt, the finding of overexpressed membranous β-cat-
enin in proliferative compartment of the hyperplastic
mucosa may represent a significant abnormality; how-
ever, it needs to be further evaluated in future studies.
Conclusion
CyCAP knockout mice develop mucosal hyperprolifera-
tion and mucosal hyperplasia early in life without expo-
sure to carcinogen and as such they represent the first
known model of spontaneous colonic hyperplasia. When
challenged by a carcinogen, CyCAP knockout mice also
develop significantly more hyperplasia and more tumors
than wild-type mice, indicating that their mucosa is more
proliferative than in WT animals. Therefore, our results
link an early premalignant change in murine colorectal
mucosa to deficiency of a glycoprotein with a role in mod-
ulation of endotoxin signalling. Further studies are neces-
sary to elucidate if this multifunctional glycoprotein may
also have a role in human preneoplastic hyperplasia, the
pathogenesis of which is largely unknown.
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